Lymphocyte gate: normative distribution of B cell-related, T cell-related and NK cell-related epitopes
| Median | (Q1, Q3) | (5%, 95%) | N | % CD19 | (Q1, Q3) | |
| % CD45 | 90 | (84, 95) | (55, 97) | 368 | ||
| CD3:CD19 | 1.8 | (1.0, 3.1) | (0.5, 6.9) | 359 | ||
| B cell antigens | ||||||
| CD19 | 32 | (20, 44) | (11, 60) | 378 | ||
| CD20 | 31 | (22, 43) | (11, 61) | 371 | 100 | (94.1, 104) |
| CD22 | 36 | (25, 48) | (13, 62) | 331 | 110 | (101.1, 125.7) |
| FMC7 | 17 | (10, 28) | (3, 43) | 349 | 57.1 | (38.5, 77.7) |
| CD23 | 25 | (15, 33) | (5, 50) | 349 | 77.8 | (57.7, 96.6) |
| CD10 | 3 | (1, 7) | (0, 20) | 371 | 9.8 | (5, 22.7) |
| CD38+CD19+ | 25 | (15, 36) | (7, 51) | 361 | 83.8 | (69.6, 93.3) |
| CD5+CD19+ | 3 | (1, 5) | (0, 10) | 373 | 8.8 | (5, 14.7) |
| Kappa+ | 17 | (12, 24) | (7, 35) | 371 | 55.6 | (50, 60.4) |
| Lambda+ | 11 | (8, 16) | (5, 23) | 370 | 36.8 | (32.8, 40.5) |
| Kappa:lambda | 1.5 | (1.3, 1.7) | (1.1, 2.2) | 370 | ||
| T cell antigens | %CD3 | |||||
| CD3 | 60 | (48, 71) | (31, 84) | 364 | ||
| CD4 | 45 | (37, 57) | (23, 70) | 365 | 80.3 | (72.3, 86.7) |
| CD8 | 13 | (9, 19) | (4, 31) | 365 | 22.5 | (16.3, 30.7) |
| CD5 | 64 | (52, 75) | (36, 86) | 373 | 105.2 | (100, 111.4) |
| CD2 | 60 | (47, 71) | (29, 82) | 281 | 98.5 | (95.6, 101.3) |
| CD7 | 58 | (44, 69) | (31, 80) | 282 | 95.8 | (91.7, 98.9) |
| CD16+CD3+ | 0 | (0, 0) | (0, 1) | 268 | 0 | (0, 0) |
| CD56+CD3+ | 0 | (0, 1) | (0, 2) | 277 | 0 | (0, 1.3) |
| CD57+CD3+ | 3 | (2, 5) | (1, 10.8) | 265 | 5 | (2.6, 10.3) |
| CD4:CD8 | 3.5 | (2.4, 5.3) | (1.1, 10.7) | 364 | ||
| CD7-negative T/NK (% CD2) | 2.7% | (−1.2, 6.5) | (−10, 14) | 279 | ||
| NK cell antigens | ||||||
| CD16+CD3− | 0 | (0, 0) | (0, 1) | 267 | ||
| CD56+CD3− | 1 | (0, 1) | (0, 4) | 266 | ||
| CD57+CD3− | 0 | (0, 0) | (0, 1) | 265 |
NK, natural killer.